Stericycle
Market Cap
US$5.1b
Last Updated
2020/07/02 23:56 UTC
Data Sources
Company Financials +
Executive Summary
Stericycle, Inc., together with its subsidiaries, provides regulated and compliance solutions to the healthcare, retail, and commercial businesses in the United States, Europe, and internationally.
Rewards
Risk Analysis
Snowflake Analysis
Moderate growth potential and overvalued.
Similar Companies
Share Price & News
How has Stericycle's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SRCL has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-0.09%
SRCL
1.8%
US Commercial Services
1.6%
US Market
1 Year Return
15.5%
SRCL
-6.1%
US Commercial Services
4.8%
US Market
Return vs Industry: SRCL exceeded the US Commercial Services industry which returned -6.1% over the past year.
Return vs Market: SRCL exceeded the US Market which returned 4.8% over the past year.
Shareholder returns
| SRCL | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.09% | 1.8% | 1.6% |
| 30 Day | -0.4% | -2.4% | 2.3% |
| 90 Day | 30.0% | 26.2% | 29.5% |
| 1 Year | 15.5%15.5% | -4.6%-6.1% | 7.1%4.8% |
| 3 Year | -26.2%-26.2% | 36.8%28.3% | 37.1%28.1% |
| 5 Year | -58.5%-58.5% | 75.4%57.7% | 67.2%48.6% |
Price Volatility Vs. Market
How volatile is Stericycle's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 months ago | Simply Wall St
Stericycle, Inc. Yearly Results: Here's What Analysts Are Forecasting For Next Year4 months ago | Simply Wall St
Is Stericycle, Inc. (NASDAQ:SRCL) Potentially Undervalued?5 months ago | Simply Wall St
Is There An Opportunity With Stericycle, Inc.'s (NASDAQ:SRCL) 37% Undervaluation?Valuation
Is Stericycle undervalued compared to its fair value and its price relative to the market?
7.2%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SRCL ($55.5) is trading below our estimate of fair value ($59.82)
Significantly Below Fair Value: SRCL is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: SRCL is unprofitable, so we can't compare its PE Ratio to the Commercial Services industry average.
PE vs Market: SRCL is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SRCL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SRCL is overvalued based on its PB Ratio (2.2x) compared to the US Commercial Services industry average (1.4x).
Next Steps
Future Growth
How is Stericycle forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
103.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SRCL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: SRCL is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SRCL's is expected to become profitable in the next 3 years.
Revenue vs Market: SRCL's revenue (0.5% per year) is forecast to grow slower than the US market (9.3% per year).
High Growth Revenue: SRCL's revenue (0.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SRCL's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Stericycle performed over the past 5 years?
-66.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SRCL is currently unprofitable.
Growing Profit Margin: SRCL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SRCL is unprofitable, and losses have increased over the past 5 years at a rate of -66.8% per year.
Accelerating Growth: Unable to compare SRCL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SRCL is unprofitable, making it difficult to compare its past year earnings growth to the Commercial Services industry (4.7%).
Return on Equity
High ROE: SRCL has a negative Return on Equity (-14.4%), as it is currently unprofitable.
Next Steps
Financial Health
How is Stericycle's financial position?
Financial Position Analysis
Short Term Liabilities: SRCL's short term assets ($1.2B) exceed its short term liabilities ($818.5M).
Long Term Liabilities: SRCL's short term assets ($1.2B) do not cover its long term liabilities ($3.3B).
Debt to Equity History and Analysis
Debt Level: SRCL's debt to equity ratio (113.8%) is considered high.
Reducing Debt: SRCL's debt to equity ratio has increased from 80.9% to 113.8% over the past 5 years.
Debt Coverage: SRCL's debt is not well covered by operating cash flow (11.3%).
Interest Coverage: SRCL is unprofitable, therefore interest payments are not well covered by earnings.
Balance Sheet
Next Steps
Dividend
What is Stericycle current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SRCL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SRCL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SRCL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SRCL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SRCL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.5yrs
Average management tenure
CEO
Cindy Miller (58yo)
1.17yrs
Tenure
US$3,215,913
Compensation
Ms. Cindy J. Miller has been the President of Stericycle, Inc. since October 1, 2018, Chief Executive Officer since May 2, 2019 and as its Director since February 28, 2019. Ms. Miller served as Chief Opera ...
CEO Compensation Analysis
Compensation vs Market: Cindy's total compensation ($USD3.22M) is below average for companies of similar size in the US market ($USD7.32M).
Compensation vs Earnings: Cindy's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.17yrs | US$3.22m | 0.0046% $235.4k | |
| Executive VP | 1.08yrs | US$1.35m | no data | |
| Executive VP | 3yrs | US$1.05m | 0.0019% $96.4k | |
| Executive VP & Chief People Officer | 1.5yrs | US$938.00k | 0.00090% $45.7k | |
| Executive Vice President of International | 1.08yrs | US$1.39m | 0.015% $748.9k | |
| Senior VP & Chief Accounting Officer | 3.17yrs | no data | 0.0058% $293.3k | |
| Vice President of Corporate Communications & Investor Relations | no data | no data | no data | |
| Executive VP and Chief Ethics & Compliance Officer | 2.25yrs | no data | 0.0015% $76.1k | |
| Executive Vice President of North American Operations | 1.5yrs | no data | 0.00072% $36.5k | |
| Executive VP & Chief Commercial Officer | 0.75yr | no data | no data |
1.5yrs
Average Tenure
58yo
Average Age
Experienced Management: SRCL's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.17yrs | US$3.22m | 0.0046% $235.4k | |
| Independent Director | 7.67yrs | US$212.49k | 0.0037% $189.8k | |
| Independent Director | 6.17yrs | US$204.99k | 0.010% $525.6k | |
| Independent Director | 3.5yrs | US$224.99k | 0.0056% $282.6k | |
| Independent Director | 2.08yrs | US$204.99k | 0.0020% $101.5k | |
| Independent Director | 2.08yrs | US$204.99k | 0.0020% $101.5k | |
| Independent Chairman of the Board | 2.33yrs | US$304.96k | 0.0056% $284.1k | |
| Independent Director | 1.33yrs | US$175.52k | no data | |
| Independent Director | 5.17yrs | US$217.46k | 0.0027% $137.0k | |
| Independent Director | 1.33yrs | US$175.54k | no data |
2.2yrs
Average Tenure
65yo
Average Age
Experienced Board: SRCL's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: SRCL insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Stericycle, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Stericycle, Inc.
- Ticker: SRCL
- Exchange: NasdaqGS
- Founded: 1989
- Industry: Environmental and Facilities Services
- Sector: Commercial Services
- Market Cap: US$5.074b
- Shares outstanding: 91.42m
- Website: https://www.stericycle.com
Number of Employees
Location
- Stericycle, Inc.
- 2355 Waukegan Road
- Bannockburn
- Illinois
- 60015
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SRCL | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Aug 1996 |
| SY9 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Aug 1996 |
| 0L9O | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Aug 1996 |
Biography
Stericycle, Inc., together with its subsidiaries, provides regulated and compliance solutions to the healthcare, retail, and commercial businesses in the United States, Europe, and internationally. It operates through three segments: North America RWCS; International RWCS; and Domestic Communication and Related Services. It collects and processes regulated and specialized waste for disposal services; and collects personal and confidential information for secure destruction, recall/return, and communication services. The company’s services also include medical waste disposal, pharmaceutical waste disposal, hazardous waste management, sustainability solutions for expired or unused inventory, secure information destruction of documents and e-media, and compliance services; and regulated recall and returns management communication, logistics, and data management services for expired, withdrawn, or recalled products. In addition, it offers compliance programs under the Steri-Safe, Clinical Services, First Practice Management, SeguriMed, and EnviroAssure brand names. The company serves healthcare businesses, including hospitals, physician and dental practices, outpatient clinics, long-term care facilities, etc.; retailers and manufacturers; financial and professional service providers; governmental entities; and other businesses. Stericycle, Inc. was founded in 1989 and is headquartered in Bannockburn, Illinois.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/07/02 23:56 |
| End of Day Share Price | 2020/07/02 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.